Immatics NV Shines at ASCO with Promising Metastatic Melanoma Therapy
Immatics NV, a German biotech company, has made significant strides in cancer immunotherapy with its IMA203 PRAME cell therapy, showing promising clinical outcomes in treating metastatic melanoma.
2 minutes to read